Hi Kronberg,
1. Again as I mentioned, Dror had previously stated that only "Active" programs in development are mentioned on the company slide deck.
The fact that OPRX-106 is not on the slide deck therefore doesn't necessarily mean they canned it entirely, just that it is not going through active (read clinical) development at the moment.
2. Just FYI royalties on net sales of 35-40% of sales are exceedingly good terms. Most of such royalties don't go higher than mid-teens.
3. On Pluristem I don't recall, but I can imagine that I did say so. Unfortunately such thinking was based on them actually successfully meeting the trial endpoints for which it seems that management even admitted having chosen the wrong endpoint to lead to approval. Had PSTI achieved the endpoint on their trials I do feel the astronomical market need in CLI, IC and Hip-Fracture would have made a much easier path to the future. Alas that did not happen.
4. Then it seems I misunderstood your timing on this talk of selling. I assumed the fact that you were discussing that now was relating to that happening soon and not in the next 5,6,7 years. As why else mention it at this juncture. But then apologies if there was confusion there.
5. It would no be that the agreements would sign for a future BO, but the terms of a current agreement can limit itself to more conservative terms. Indeed perhaps in time the companies you mention may be interested in buying though.
Best,
Spidey
